Source: www.medscape.com Author: Zosia Chustecka In patients with head and neck cancer who do not undergo surgery, chemotherapy with nonplatinum agents given concurrently with radiotherapy offers clear benefits for recurrence and survival, say the authors of one of the largest and longest randomized trials carried out in this patient group. Event-free survival in patients who [...]
Continue reading...Tuesday, November 3, 2009
Source: www.reuters.com Author: press release YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that an oral presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting reported positive 48-month survival data for its [...]
Continue reading...Monday, August 24, 2009
Source: news.prnewswire.com Author: press release PCI Biotech Holding ASA, the Norwegian drug delivery company focusing on effective delivery of cancer therapeutics, today announced that the first patient has received treatment in the Phase I/II trial with the lead candidate Amphinex(R), which uses a new approach called photochemical internalisation. The patient was treated at the University [...]
Continue reading...Tuesday, July 7, 2009
Source: www.oncologystat.com Author: staff Intensity-modulated radiotherapy significantly reduces the risk of subjective xerostomia by about 50% in patients with pharyngeal tumors, according to the first results of the multicenter, phase III PARSPORT trial. Cancer Research UK’s PARSPORT (Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who [...]
Continue reading...Wednesday, May 6, 2009
Source: www.genengnews.com Author: staff An effort is under way at the University of Houston to use technologies with origins in the automobile industry to develop new tools that will help doctors and technicians better plan radiation therapy for patients with head and neck cancer. Dr. Ali Kamrani, founding director of the Design and Free Form [...]
Continue reading...Wednesday, September 3, 2008
Source: San Antonio Business Journal (www.bizjournals.com) Author: staff Azaya Therapeutics Inc. has licensed a technology that could be beneficial in treating head and neck cancers, the company said Wednesday. The technology involves the use of liposomes to deliver radiation into the head and neck tumors through a direct injection. Company officials say they may be [...]
Continue reading...
Thursday, November 5, 2009
0 Comments